Bioventix Share Discussion Threads

[panic investor] 11/8/2017 11:50

Spotted that too - increased here yesterday myself

[ragehammer] 11/8/2017 11:48

There was a small write up in the Evening Standard following the UK Buffettology fund increasing its stake. It described Bioventix as "bombproof". It's probably caused the latest little bit of excitement.

[stepone68] 11/8/2017 11:42

Bit of excitement in the share price for the first time in a few months. Some interest ahead of a trading update this month?

[gsbmba99] 01/8/2017 14:45

Another article on the recently revealed Bateman beta amyloid blood test for Alzheimers. More positive comments on the significance of, need for and usage of a blood based test. Not clear whether this Bateman test can be adapted to run on the workhorse lab diagnostic machines that a Pre Diagnostics/Bioventix test would target.

[piedro] 28/7/2017 12:35

gsbmba99, thank you - looks like i've got research work to do.

Much more interesting than watching sp's :-)

[gsbmba99] 28/7/2017 07:49

Sharw, I've edited the post and hopefully the links work. Piedro, the links I included from the Pre Diagnostics website are full text research papers published by, amongst others, Tormod Fladby whose research forms the basis for Pre Diagnostics' work. There are more at the Pre Diagnostics website (>New invention >R&D History) Bioventix wasn't involved in the original research but has since announced a collaboration ( )

[sharw] 28/7/2017 00:17

gsbmba99 -

Your links do not work because you add parentheses on both ends without a space. For links to work there must be a space at both ends.

Piedro - delete those additions and they will work.

[piedro] 27/7/2017 22:25

gsbmba99,
Thank you for postings though I have not been able to open the links.

Alzheimer's testings are certainly a topic to put off most but I have found a couple of sites that explain the situation in simple terms ...

Beta Amyloid Protein, Plaque, and Alzheimer's


Quest for biomarkers (approx. 17 min.)


... which brings me to your question before I dive into further research:
"What about Pre Diagnostics/Bioventix?"

and can you point me to a reference where Bioventix is said to be involved in such research?

TIA.

[gsbmba99] 27/7/2017 20:11

The Bateman test revealed recently measures the ratio of beta amyloid 1-42 to beta amyloid 1-40 ( ). In a study of 41 people it was 89% accurate in being able to characterise people as beta amyloid positive or negative. What about Pre Diagnostics/Bioventix? The beta amyloid build up is caused when it begins to naturally degrade at a slower rate causing the formation of amyloid plaques. The Pre-diagnostics research ( ) ( )focuses on the mid range of beta amyloid where they think the natural degradation is impacted. So, it would seem they are seeking to identify diseased or abnormal beta amyloid incapable of being naturally degraded in the bloodstream by developing an antibody to bind to a different part of beta amyloid than existing antibodies.

[gsbmba99] 27/7/2017 19:53

Did a bit more reading on beta amyloid. Interesting chart here ( ). If you click only AD vs Ctrl (Plasma/Serum), the chart, if I've interpreted it correctly, suggests that no single biomarker is statistically significant in the Alzheimers Disease (AD) cohort vs the control group when measured in blood. You can change the settings to look at AD vs Ctrl in CSF and there are multiple biomarkers that are statistically significant. This is consistent with the beta amyloid theory that excess amounts are deposited in the brain. Any test simply looking for the amount of beta amyloid (or Tau) in blood is unlikely to be useful because the amount of beta amyloid in the blood stream isn't different between those with AD and those without.

[gsbmba99] 22/7/2017 10:42

Slightly dated article looking at developments in automated CSF assays ( According to the article, Roche, Fujirebio and Euroimmun are introducing automated, CE marked CSF assays for beta amyloid 1-42 (and others) in 2017. Fujirebio is in the market in Europe already, Roche supposedly June and Euroimmun (now owned by Perkin-Elmer) later in the year. Euroimmun are using an antibody developed by Adx Neurosciences ( who also appear to be well advanced with a blood test. Fujirebio looks to be using an antibody from Eli Lilly ("a license for the use of amyloid beta monoclonal antibodies contained in this product under patents US 6114133, US7811769, and EP 0792458 has been obtained from Eli Lilly" from Roche unclear. Article also notes issues with generating consistent results.

[gsbmba99] 21/7/2017 07:53

The Alzheimers Association International Conference just concluded in London ( Go to Blood Biomarker for Amyloid Plaques. Dr. Bateman: “We’re excited because the results also suggest that blood-derived amyloid-beta may be useful as a rapid and inexpensive screening test for brain amyloidosis, and may be able to identify people who are at higher risk of Alzheimer’s disease very early in the process.” ... "Having a simple and inexpensive blood test for screening is likely to greatly accelerate clinical trials to find Alzheimer’s drugs. And, it could facilitate widespread treatment when effective anti-amyloid therapeutics are developed,” Bateman added. Not directly related to BVXP as I think it's a different test but useful in the ongoing effort to establish clinical usefulness of blood based beta amyloid testing.

[ilovefrogs] 10/7/2017 13:47

Yes. There's clearly a village somewhere missing it's idiot. If Opodia tells us where he is, we can let them know so that they can come and collect him....;-)

[tadders2] 10/7/2017 13:45

Ilovefrogs....you are nearly right...I think he has two neurons ,unfortunately one is inhibitory.

[ilovefrogs] 10/7/2017 13:22

Hi Opodio my single-brain celled friend - Please do explain how a firm which specializes in the development of sheep monoclonal antibodies for use in immunodiagnostics and clinical testing faces competition from generics. Do that, and perhaps we'll take you seriously! I thin you have your work cut out though........

[trident5] 09/7/2017 19:59

You need to sell too CC - otherwise Opodio will have to take his shorts off, and that's not a pretty sight.

[crazycoops] 09/7/2017 19:38

"A generic rival launch" LOL! You clearly have no idea about the BVXP business model.

[trident5] 09/7/2017 13:26

So insightful. I must sell my shares tomorrow.

[opodio] 09/7/2017 13:05

Reckon there be a generic rival launch which will kill the business

[tadders2] 09/7/2017 13:03

What a lot of nonsense

[opodio] 09/7/2017 12:57

Profit warning coming I suspect this will fall to 6 pounds

Don't forget there were massive Director sales End of last year they know party is over

[melody9999] 07/7/2017 11:43

tree shake?

[gsbmba99] 14/6/2017 18:12

Very technical write-up of the transition from TnI to hsTnI at an Italian hospital using the Abbott test.

[gsbmba99] 14/6/2017 17:48

"The introduction of hsTnI has not resulted in a shorter length of hospital stay for patients undergoing troponin testing. Troponin testing became more frequent after the introduction of the new assay which may have resulted in extra, unnecessary admissions." An unsurprising conclusion given: "All patients who had 2 hsTnI requests ended up being admitted to hospital, even if both were undetectable." Seems unusually conservative to admit everyone with two sequential undetectable hsTnI tests given the sensitivity of the test. Potentially more relevant longer term: "No patient who had an undetectable 1st troponin had a positive 2nd troponin."

[trident5] 09/6/2017 10:18

Er, it has been going up.